Off‑the‑shelf and on‑target: how iPSC‑derived CAR‑T cells could democratize autoimmune cell therapy
Year: 2026
Type: article
Abstract: “The future of autoimmunity is being reprogrammed in real time, and iPSC CAR‑T cells are helping to write the code.”Abi Pinchbeck, Commissioning Editor, Cell & Gene Therapy Insights, speaks with John (Bobby) Goulding, Director, Corporate Strategy, Fate Therapeutics, who takes an in‑depth look at induced pluripotent stem cell (iPSC)-derived allogeneic CAR‑T cells and their potential clinical application in autoimmune disease, including safety‑by‑design considerations, clinical trial considerations, manufacturing scalability, and democratizing outpatient access.
Source: Cell and Gene Therapy Insights
Author: John Goulding
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W7154987213
FWCI:
Cites:
Cited by:
Related to: